Tag: Tremfya

Brodalumab effective in treating active psoriatic arthritis

Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis

byDeepti Shroff

June 5, 2026

1. The FDA has expanded the label for guselkumab (Tremfya) to include evidence that it can inhibit progression of structural ...

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

byDeepti Shroff

June 3, 2026

Pfizer and Innovent deepen the China biotech licensing wave Pfizer is making another large oncology bet, this time through a ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: Tremfya

Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits